S-8 1 d611393ds8.htm S-8 S-8

As filed with the Securities and Exchange Commission on January 12, 2024

Registration No. 333-          

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

 

REGULUS THERAPEUTICS INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   26-4738379

(State or other jurisdiction of

incorporation or organization)

  

(I.R.S. Employer

Identification No.)

4224 Campus Point Court, Suite 210

San Diego, CA

   92121
(Address of Principal Executive Offices)   (Zip Code)

2019 Equity Incentive Plan, as amended

2022 Employee Stock Purchase Plan

2021 Inducement Plan, as amended

(Full titles of the plans)

Joseph P. Hagan

Chief Executive Officer

Regulus Therapeutics Inc.

4224 Campus Point Court, Suite 210

San Diego, CA 92121

(858) 202-6300

(Name, address, including zip code, and telephone number, including area code, of agent for service)

Copies to:

Thomas A. Coll, Esq.

Asa M. Henin, Esq.

Cooley LLP

10265 Science Center Drive

San Diego, California 92121

Tel: (858) 550-6000

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large Accelerated filer   ☐    Accelerated filer   ☐
Non-accelerated filer   ☒    Smaller reporting company   ☒
Emerging growth company   ☐     

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐

 

 

 

REGISTRATION OF ADDITIONAL SHARES

PURSUANT TO GENERAL INSTRUCTION E

This Registration Statement is being filed for the purpose of increasing the number of securities of the same class as other securities for which Registration Statements of the registrant on Form S-8 relating to the same employee benefit plans are effective.

The registrant previously registered shares of its Common Stock for issuance under the Regulus Therapeutics Inc. 2019 Equity Incentive Plan under Registration Statements on Form S-8 filed with the Securities and Exchange Commission (the “SEC”) on August  22, 2019 (File No. 333-233414), January 22, 2020 (File No. 333-236020), February 4, 2021 (File No.  333-252733), January 12, 2022 (File No.  333-262112), January 11, 2023 (File No.  333-269184) and June 29, 2023 (File No. 333-273027). Pursuant to General Instruction E to Form S-8, this Registration Statement hereby incorporates by reference the contents of the Registration Statements referenced above.

The registrant previously registered shares of its Common Stock for issuance under the 2022 ESPP under Registration Statements on Form S-8 filed with the SEC on August 11, 2022 (File No. 333-266800) and January 11, 2023 (File No. 333-269184). Pursuant to General Instruction E to Form S-8, this Registration Statement hereby incorporates by reference the contents of the Registration Statements referenced above.

The registrant previously registered shares of its Common Stock for issuance under the 2021 Inducement Plan under Registration Statements on Form S-8 filed with the SEC on November 29, 2021 (File No. 333-261402) and January 11, 2023 (File No. 333-269184). Pursuant to General Instruction E to Form S-8, this Registration Statement hereby incorporates by reference the contents of the Registration Statements referenced above.

PART II

Item 3. Incorporation of Documents by Reference

The following documents filed by the registrant with the SEC are incorporated by reference into this registration statement (other than portions of such documents that are furnished but not filed or are otherwise not incorporated into registration statements pursuant to the applicable rules promulgated by the SEC):

 

  •  

the registrant’s Annual Report on Form  10-K for the year ended December 31, 2022, filed with the SEC on March 23, 2023;

 

  •  

the information specifically incorporated by reference into the registrant’s Annual Report on Form 10-K for the year ended December 31, 2022 from the registrant’s definitive proxy statement on  Schedule 14A relating to its 2023 annual meeting of stockholders, filed with the SEC on April 28, 2023;

 

  •  

the registrant’s Quarterly Reports on Form 10-Q for the quarters ended March 31, 2023, June 30, 2023 and September 30, 2023, filed with the SEC on May  11, 2023, August  8, 2023 and November 9, 2023, respectively;

 

  •  

the registrant’s Current Reports on Form 8-K, filed with the SEC on January  6, 2023, April 13, 2023, June  12, 2023, June 14, 2023 and June  23, 2023; and

 

  •  

the description of the registrant’s common stock contained in the registrant’s registration statement on Form 8-A, filed with the SEC on September 27, 2012, including any amendments or reports filed for the purpose of updating such description.

All reports and other documents filed by the registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items and other portions of documents that are furnished but not filed or are otherwise not incorporated into registration statements pursuant to the applicable rules promulgated by the SEC, after the date of this registration statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this registration statement from the date of filing such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated herein by reference shall be deemed to be modified or superseded for purposes of this registration statement to the extent that a statement herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes that statement. Any such statement so modified or superseded shall not constitute a part of this registration statement, except as so modified or superseded.

EXHIBIT INDEX

 

Exhibit

Number

   

Description

  4.1    Amended and Restated Certificate of Incorporation of the registrant (incorporated by reference to Exhibit 3.1 to the registrant’s Quarterly Report on Form 10-Q, filed with the SEC on August 3, 2016).
  4.2    Certificate of Amendment of Amended and Restated Certificate of Incorporation of the registrant (incorporated by reference to Exhibit 3.1 to the registrant’s Current Report on Form 8-K, filed with the SEC on October 2, 2018).
  4.3    Certificate of Amendment of Amended and Restated Certificate of Incorporation of the registrant (incorporated by reference to Exhibit 3.1 to the registrant’s Current Report on Form 8-K (File No. 001-35670), filed with the SEC on June 16, 2021).
  4.4    Certificate of Amendment of Amended and Restated Certificate of Incorporation of the registrant. (incorporated by reference to Exhibit 3.1 to the registrant’s Current Report on Form 8-K (File No. 001-35670), filed with the SEC on June 27, 2022).
  4.5    Amended and Restated Bylaws of the registrant (incorporated by reference to Exhibit  3.1 to the registrant’s Current Report on Form 8-K, filed with the SEC on June 8, 2016).
  4.6    Form of Common Stock Certificate of the registrant (incorporated by reference to Exhibit  4.2 to the registrant’s Quarterly Report on Form 10-Q, filed with the SEC on August 11, 2022).
  5.1    Opinion of Cooley LLP.
23.1    Consent of Independent Registered Public Accounting Firm.
23.2    Consent of Cooley LLP. Reference is made to Exhibit 5.1.
24.1    Power of Attorney. Reference is made to the signature page hereto.
99.1    Regulus Therapeutics Inc. 2019 Equity Incentive Plan, as amended (incorporated by reference to Exhibit 99.1 to the registrant’s current report on Form 8-K (File No. 001-35670), filed with the SEC on June 14, 2023).
99.2    Form of Stock Option Grant Notice and Option Agreement under the Regulus Therapeutics Inc. 2019 Equity Incentive Plan (incorporated by reference to Exhibit 99.2 to the registrant’s Registration Statement on Form S-8 (File No. 333-233414), filed with the SEC on August 22, 2019).
99.3    Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement under the Regulus Therapeutics Inc. 2019 Equity Incentive Plan (incorporated by reference to Exhibit 99.3 to the registrant’s Registration Statement on Form S-8 (File No. 333-233414), filed with the SEC on August 22, 2019).
99.4    2022 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.1 to the registrant’s Quarterly Report on Form 10-Q (File No. 001-35670), filed with the SEC on August 11, 2022).
99.5    2021 Inducement Plan, as amended.
99.6    Form of Stock Option Grant Notice, Form of Option Agreement and Notice of Exercise under the Regulus Therapeutics Inc. 2021 Inducement Plan (incorporated by reference to Exhibit 99.6 to the registrant’s Registration Statement on Form S-8 (File No. 333-269184), filed with the SEC on January 11, 2023).
107    Filing Fee Table

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on January 12, 2024.

 

REGULUS THERAPEUTICS INC.
By:  

/s/ Joseph P. Hagan

  Joseph P. Hagan
  President and Chief Executive Officer

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Joseph P. Hagan as his or her true and lawful attorney-in-fact and agent, with full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent or his substitute may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

 

Signature

   

Title

   

Date

/s/ Joseph P. Hagan

Joseph P. Hagan

   

Chief Executive Officer and Member

of the Board of Directors

(Principal Executive Officer)

    January 12, 2024

/s/ Cris Calsada

    Chief Financial Officer    January 12, 2024
Cris Calsada    (Principal Financial Officer)   

/s/ Daniel Penksa

   

Vice President of Finance & Controller

(Principal Accounting Officer)

    January 12, 2024
Daniel Penksa   

/s/ Preston S. Klassen

Preston S. Klassen, M.D.

    President and Member of the Board of Directors    January 12, 2024

/s/ Stelios Papadopoulos

Stelios Papadopoulos, Ph.D.

    Chairman of the Board of Directors    January 12, 2024

/s/ David Baltimore

David Baltimore, Ph.D.

    Member of the Board of Directors    January 12, 2024

/s/ Kathryn J. Collier

Kathryn J. Collier

    Member of the Board of Directors    January 12, 2024

/s/ Alice S. Huang

Alice S. Huang, Ph.D.

    Member of the Board of Directors    January 12, 2024

/s/ Jake R. Nunn

    Member of the Board of Directors    January 12, 2024
Jake R. Nunn      

/s/ William H. Rastetter

William H. Rastetter, Ph.D.

    Member of the Board of Directors    January 12, 2024

/s/ Hugh Rosen

Hugh Rosen, M.D., Ph.D.

    Member of the Board of Directors    January 12, 2024

/s/ Pascale Witz

Pascale Witz

    Member of the Board of Directors    January 12, 2024